SELEGILINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Selegiline Hydrochloride patents expire, and what generic alternatives are available?
Selegiline Hydrochloride is a drug marketed by Apotex, Lannett Co Inc, Novitium Pharma, Rising, Apotex Inc, Bayshore Pharms Llc, Chartwell Molecules, Cosette, Dash Pharms Natco, G And W Labs Inc, I3 Pharms, and Somerset. and is included in fourteen NDAs.
The generic ingredient in SELEGILINE HYDROCHLORIDE is selegiline hydrochloride. There are seventeen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the selegiline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Selegiline Hydrochloride
A generic version of SELEGILINE HYDROCHLORIDE was approved as selegiline hydrochloride by I3 PHARMS on April 1st, 1997.
Summary for SELEGILINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 12 |
NDAs: | 14 |
Finished Product Suppliers / Packagers: | 8 |
Raw Ingredient (Bulk) Api Vendors: | 67 |
Clinical Trials: | 38 |
Patent Applications: | 668 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SELEGILINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for SELEGILINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Ibadan | Phase 1/Phase 2 |
László Mangel | Phase 2 |
E-Group ICT Software Informatikai Zrt. | Phase 2 |
Pharmacology for SELEGILINE HYDROCHLORIDE
Drug Class | Monoamine Oxidase Inhibitor Monoamine Oxidase Type B Inhibitor |
Mechanism of Action | Monoamine Oxidase Inhibitors Monoamine Oxidase-B Inhibitors |